Surveillance of Neisseria meningitidis carriage four years after menACWY vaccine implementation in the Netherlands reveals decline in vaccine-type and rise in genogroup e circulation

Carriage of Neisseria meningitidisis an accepted endpoint in monitoring meningococcal vaccine effects. We applied molecular methods to assess the impact of menACWY vaccine implementation on meningococcal carriage and genogroup-specific prevalence in young adults in Fall of 2022, four years after the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Vaccine Ročník 41; číslo 34; s. 4927 - 4932
Hlavní autoři: Miellet, Willem R., Pluister, Gerlinde, Sikking, Meike, Tappel, Marcia, Karczewski, Jurgen, Visser, Linda J., Bosch, Thijs, Trzciński, Krzysztof, Mariman, Rob
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier Ltd 31.07.2023
Elsevier Limited
Témata:
Age
Allergy and Immunology
Carriage surveillance
decline
Genotype
Glycerol
Humans
Immunization
Ions
menACWY vaccine
Meningococcal Infections - epidemiology
Meningococcal Infections - prevention & control
Meningococcal Vaccines
Meningococcus
monitoring
Neisseria meningitidis
Neisseria meningitidis - genetics
Netherlands
Netherlands - epidemiology
Population
Reduction
Surveillance
Vaccines
Vaccines, Combined
Young Adult
Young adults
Netherlands
Germany
Carriage surveillance
Neisseria meningitidis
menACWY vaccine
Meningococcus
ISSN:0264-410X, 1873-2518, 1873-2518
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Carriage of Neisseria meningitidisis an accepted endpoint in monitoring meningococcal vaccine effects. We applied molecular methods to assess the impact of menACWY vaccine implementation on meningococcal carriage and genogroup-specific prevalence in young adults in Fall of 2022, four years after the introduction of the tetravalent vaccine in the Netherlands. The overall carriage rate of genogroupable meningococci was not significantly different compared to a pre-menACWY cohort investigated in 2018 (20.8 % or 125 of 601 versus 17.4 % or 52 of 299 individuals, p = 0.25). Of 125 carriers of genogroupable meningococci, 122 (97.6 %) were positive for either vaccine-types menC, menW, menY or genogroups, menB, menE, and menX, which are not targeted by the menACWY vaccine. Compared with a pre-vaccine-implementation cohort, there was 3.8-fold reduction (p < 0.001) in vaccine-type carriage rates and 9.0-fold increase (p < 0.0001) in non-vaccine type menE prevalence. We observe a reduction in menW and menY and an increase in menE, which suggest that implementation of menACWY vaccine affected carriage.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2023.06.078